* Fails to meet secondary goal of efficacy
* Says trial met main goal of safety
March 11 - Supernus Pharmaceuticals said its experimental
drug to treat attention deficit hyperactivity disorder (ADHD)
proved safe and well tolerated in a mid-stage trial.
ADHD is a common nervous system disorder, characterised by
impulsivity and attention problems, which according to the
company affects 3-5 percent of adults in the United States.
The Rockville, Maryland-based drugmaker, which expects its
Nasdaq debut under the ticker "SUPN", said the drug SPN-812 met
the primary goal of safety and tolerability in 52 adults,
studied under the trial.
In December, the company filed with U.S. securities
regulators to raise up to $100 million in an initial public
The drug, however, failed to meet the secondary goal of
showing statistically significant improvement in ADHD symptoms
as compared to a dummy pill.
(Reporting by Krishnakali Sengupta in Bangalore; Editing by
(firstname.lastname@example.org; within U.S. +1 646 223
8780; outside U.S. +91 80 4135 5800; Reuters